|
EnerFlex® IMPROVES LIVER HEALTH
Most drugs generally produce one type of liver cell injury in exposed or susceptible individuals, although some drugs are known to cause more than one type of injury. |
Liver is the major site for drug metabolism, it is not surprising that drug toxicity and adverse drug reactions frequently affect the liver. More than 1100 drugs have been implicated in causing liver disease at least in rare occasion. Up to 25% of cases of fulminant hepatic failure and 20-50% of cases of non-viral chronic hepatitis may be drug-induced.
The type of liver cell injury may be intrinsic and dose dependent or may be idiosyncratic and dose-independent. The mechanism of intrinsic hepatotoxins may relate either to formation of free radicals or electrophilic intermediates, or to production of reactive oxygen species, which like free radicals, leads to lipid peroxidation.
REF: UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY
www.uscap.org |
In 2003, we conducted 2 observational studies with our novel soy formulas namely EnerFlex® D-Diet and EnerFlex® Combo (combining 20g EnerFlex® and 20g EnerFlex® D-Diet) in Type 2 Diabetes and Obese subjects respectively found to be LIVER PROTECTIVE. In 2004, we developed a new formula exclusive to doctors’ market deriving from the foundation of EnerFlex® Combo called EnerFlex® Forté and a similar protocol to EnerFlex® Combo was conducted. The results are summarized in the table below: |
Liver Function
Parameters (mean value) |
Baseline
(n=32, M=8 F=24) |
Post-Treatment EnerFlex® Forté 40g BID (28 days) |
% Change |
Baseline
(n=23, M=1 F=22) |
Post-Treatment EnerFlex® Combo 40g BID (28 days) |
Baseline
(n=86, M=47 F=39) |
Post-Treatment EnerFlex® D-Diet 40g OD (12 weeks) |
| Total Protein g/L |
72 |
73 |
1.4 |
77 |
76 |
73 |
72 |
| Total Albumin, g/L |
44 |
44 |
- |
43 |
43 |
42 |
42 |
| Globulin, g/L |
28 |
28 |
- |
34 |
33 |
31 |
30 |
| A/G Ratio |
1.6 |
1.58 |
-1.3 |
1.28 |
1.30 |
1.37 |
1.44 |
| Total Bilirubin, μmol/L |
12.4 |
11.9 |
-0.8 |
9 |
9 |
12.5 |
11.8 |
| Alkaline Phosphatase, U/L |
69 |
66 |
-4.3 |
87 |
81 |
74 |
72 |
| G-GT, U/L |
44 |
33 |
-25 |
34 |
30 |
51 |
47 |
| AST, U/L |
32 |
30 |
-6.3 |
29 |
22 |
45 |
33 |
| ALT, U/L |
40 |
33 |
-17.5 |
27 |
23 |
46 |
32 |
| Special note: We noticed that the longer the patients are on the products, the better the normalization of liver function parameters particularly ALT, Total Bilirubin, AST and GGT. 65% of Type 2 Diabetes subjects on 40g EnerFlex® D-Diet had their ALT normalized after 12 weeks. |
EnerFlex® Combo formulation has been further improved in 2007 and it is now called EnerFlex® CONTOUR.
PRIOR TO THE OBSERVATIONAL STUDIES, WE HAD CONSTANTLY RECEIVING POSITIVE FEEDBACK FROM PATIENTS WITH LIVER DISORDERS (FATTY LIVER, ACUTE HEPATITIS, HEPATITIS CARRIERS, ALCOHOLIC HEPATITIS). IT IS NOW SURPRISE THAT ENERFLEX HELPS TO REJUVENATE LIVER FUNCTIONS SIMPLY BECAUSE IT PROVIDES THE FUNDAMENTAL NUTRIENTS THAT ARE REQUIRED BY THE LIVER TO FUNCTION OPTIMALLY IN ADDITION TO THE ANTIOXIDANTS (BOTH EXOGENOUS) AND ENDOGENOUS (BY PROVIDING ALL ESSENTIAL BUILDING BLOCKS/NUTRIENTS FOR ENDOGENOUS ANTIOXIDANTS FORMATION IN THE BODY) |
Half Food... Half Medicine
effect of EnerFlex® Forté/EnerFlex® Combo / EnerFlex® D-Diet in improving and keeping Liver Function Markers at normal levels
Pre-Post data indicate % of subjects at normal liver function markers
Based on the observed data, the following mechanisms were proposed to predict the effect on liver function by EnerFlex® Forté/ EnerFlex® D-Diet / EnerFlex® Combo:
- Reversal of liver cell damage indicated by reduction of cytosol enzyme-ALT, mitochondrial enzyme-AST and microsomal enzyme-GGT
- Enhanced detoxification pathways via improvement in bowel movement by soy oligosaccharide (prebiotic) and organic potassium (modulator of parasympathetic-sympathetic nervous system)
- Supply of essential nutrients for healthy liver cell function by glutamine, glycine, cysteine amino acids, antioxidants, carotenoids, folic acid, lecithin and essential amino acids.
|
|
